Fibroblast Fatty-Acid Oxidation Flux Assays Stratify Risk in Newborns with Presumptive-Positive Results on Screening for Very-Long Chain Acyl-CoA Dehydrogenase Deficiency by Olpin, Simon et al.
Syddansk Universitet
Fibroblast Fatty-Acid Oxidation Flux Assays Stratify Risk in Newborns with
Presumptive-Positive Results on Screening for Very-Long Chain Acyl-CoA
Dehydrogenase Deficiency
Olpin, Simon; Clark, Shirley; Dalley, Jane; Andresen, Brage Storstein; Croft, Joanne; Scott,
Camilla; Khan, Aneal; Kirk, Richard J.; Sparks, Rebecca; Chard, Marisa; Chan, Alicia;
Glamuzina, Emma; Bastin, Jean; Manning, Nigel J.; Pollitt, Rodney J.
Published in:
International Journal of Neonatal Screening
DOI:
10.3390/ijns3010002
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Olpin, S., Clark, S., Dalley, J., Andresen, B. S., Croft, J., Scott, C., ... Pollitt, R. J. (2017). Fibroblast Fatty-Acid
Oxidation Flux Assays Stratify Risk in Newborns with Presumptive-Positive Results on Screening for Very-Long
Chain Acyl-CoA Dehydrogenase Deficiency. International Journal of Neonatal Screening, 3(1), [2]. DOI:
10.3390/ijns3010002
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Nov. 2018
International Journal of
Neonatal Screening
Article
Fibroblast Fatty-Acid Oxidation Flux Assays Stratify
Risk in Newborns with Presumptive-Positive Results
on Screening for Very-Long Chain Acyl-CoA
Dehydrogenase Deficiency
Simon E. Olpin 1,*, Shirley Clark 1, Jane Dalley 1, Brage S. Andresen 2, Joanne Croft 1,
Camilla A. Scott 1, Aneal Khan 3, Richard J. Kirk 4, Rebecca Sparkes 3, Marisa Chard 3,
Alicia Chan 5, Emma Glamuzina 6, Jean Bastin 7, Nigel J. Manning 1 and Rodney J. Pollitt 1
1 Department of Clinical Chemistry, Sheffield Children’s Hospital Sheffield, Sheffield S10 2TH, UK;
shirley.clark@sch.nhs.uk (S.C.); jane.dalley@sch.nhs.uk (J.D.); joanne.croft@sch.nhs.uk (J.C.);
camilla.scott@sch.nhs.uk (C.A.S.); evemanning@talktalk.net (N.J.M.); rodney.pollitt@sch.nhs.uk (R.J.P.)
2 Department of Biochemistry and Molecular Biology, University of Southern Denmark,
DK-5230 Odense M, Denmark; bragea@bmb.sdu.dk
3 Department of Medical Genetics & Paediatrics, Alberta Children’s Hospital, Calgary, AB T3B 6A8, Canada;
khaa@ucalgary.ca (A.K.); rebecca.sparkes@ahs.ca (R.S.); marisa.chard@ahs.ca (M.C.)
4 Department of Molecular Genetics, Sheffield Children’s Hospital, Sheffield S10 2TH, UK;
richard.kirk@sch.nhs.uk
5 Department of Medical Genetics, University of Alberta, Calgary, AB T3B 6A8, Canada;
alicia.chan@albertahealthservices.ca
6 National Metabolic Service, Starship Children’s Hospital, Auckland 1042, New Zealand;
eglamuzina@adhb.govt.nz
7 Inserm U747, Université Paris Descartes, UFR Biomédicale des Saints-Pères, 75270 Paris CEDEX 06, France;
jean.bastin@inserm.fr
* Correspondence: simon.olpin@sch.nhs.uk; Tel.: +44-114-271-7267
Academic Editor: Ralph Fingerhut
Received: 13 January 2017; Accepted: 17 February 2017; Published: 24 February 2017
Abstract: Very-long chain acyl-CoA dehydrogenase deficiency (VLCADD) is a clinically
heterogeneous disorder with three major phenotypes: severe neonatal/infantile, milder childhood
and late onset myopathic. VLCADD is genetically heterogeneous with numerous pathogenic
mutations and variants of uncertain significance. VLCADD is included in many newborn screening
programs but these suffer from high false positive rates, primarily due to positive screens in
heterozygotes. Separating these and newborns with two low-risk “mild” variants from clinically at
risk patients can be problematic, as clinical and biochemical markers are often unreliable, particularly
in stable neonates. We have measured fibroblast fatty acid oxidation flux using [9,10-H3]myristic
acid and [9,10-H3]oleic acid from 69 clinically presenting VLCADD patients including myopathic
and infantile phenotypes and 13 positive newborn screened patients. We also measured fibroblast
VLCADD enzyme activity by UV-HPLC detection of product in a sub-set of patients and compared
these results to oleate FAO-flux. Fibroblast enzyme assay by UV-HPLC detection failed to clearly
discriminate between some clinically presenting VLCADD patient cell lines and cell lines from
some simple heterozygotes. FAO-flux clearly discriminated between clinically presenting VLCADD
patients and the false positive screened patients. FAO-flux at 37 ◦C provides information as to the
likely clinical phenotype but FAO-flux at 41 ◦C is the best discriminator for identifying clinically at
risk patients.
Keywords: VLCAD very long chain acyl-CoA dehydrogenase; newborn screening; false positive;
oleic acid oxidation; fatty acid oxidation flux; enzyme assay
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1. Introduction
Newborn (NB) screening programs in much of Europe and in other countries around the
world including the USA, Canada, New Zealand and Australia include very long-chain acyl-CoA
dehydrogenase deficiency (VLCADD OMIM 201475) [1–5]. Currently, the only fatty acid oxidation
disorder included in the UK newborn screening program is medium chain acyl-CoA dehydrogenase
(MCAD OMIM 201450) deficiency [6].
VLCADD can present with three major phenotypes: a severe neonatal/infantile form, with early
onset non-ketotic hypoglycemia, a high incidence of cardiomyopathy and high mortality; a milder
childhood form, usually with hypoketotic hypoglycemia as the main presenting feature, often with
exercise intolerance; and rhabdomyolysis, particularly in older children, and a late onset myopathic
form in adults [7,8].
Newborn screening for VLCADD suffers from a high false positive rate due to false positive results
in many heterozygotes and to elevated acylcarnitines including C14:1 in some catabolic neonates
even in the absence of ACADVL mutations. In addition, presumptive positive screened patients are
often treated before a definitive diagnosis is established and biochemical markers of disease may
diminish or even normalize [9,10]. There is considerable molecular heterogeneity of ACADVL with new
variants of uncertain significance and mild mutations resulting in significant residual enzyme function.
This, in conjunction with unreliable biochemical markers, not infrequently poses real difficulties in
separating infants at risk of disease from those who do not require continued intervention or follow
up [11–13]. Functional assays such as very long-chain acyl-CoA dehydrogenase (VLCAD) activity
in lymphocytes or acylcarnitine profiles following palmitate loading in fibroblasts are useful tools in
these difficult cases, though they are by no means always definitive [11,14–17]. Some patients even
in the presence of two ACADVL mutations may have relatively high residual lymphocyte enzyme
activity and are considered to be at low risk of disease [11]. Fibroblast fatty acid oxidation studies
using [9,10-H3]oleic acid alone or in combination with other tritiated fatty acids have been proposed
as offering an improved alternative approach in the differential classification of these patients [18–21].
In this study, we report fatty acid oxidation flux (FAO-flux) by measuring [9,10-H3]myristic acid and
[9,10-H3]oleic acid oxidation in fibroblast cell lines from several patient groups and compare results of
FAO-flux with fibroblast VLCADD enzyme activity.
2. Patients
Over the past 25 years, we have received 69 fibroblast cell lines from clinically symptomatic
patients in whom we could confirm a diagnosis of VLCADD. Patients presenting either as
neonates/infants/young children with primarily cardiomyopathy and/or hypoglycemic episode(s)
were classified as “infantile” VLCADD (n = 47) and patients diagnosed as older children/adults with
myalgia/exercise intolerance/rhabdomyolysis were classified as “myopathic” VLCADD (n = 22).
We have also received fibroblast cell lines from 13 presumptive positive neonates from centers outside
the UK that routinely undertake newborn screening for VLCAD deficiency. Eight of these were shown
on full genetic and biochemical investigation not to have supportive evidence of VLCADD; i.e., only
one or no mutation founds (5 cell lines), homozygous for the common “benign” Pacific mutation
(c.1226C>T; p.Thr409Met) (2 cell lines) [5], or second mutation of unknown significance with enzyme
activity by UV-HPLC >100% (1 cell line). These therefore were termed false positives (eight cell lines
in total, Table 1).
Three newborn screened patients were considered true positives. One patient was a sibling of a
previous symptomatic neonate that died on Day 1 with two pathogenic mutations in the ACADVL
gene (cell line 12). The second was a neonate with one known pathogenic mutation plus a predicted
pathogenic mutation (cell line 233). A third patient (cell line 18) presented with one mutation of
unknown pathogenicity plus one predicted pathogenic mutation and enzyme activity measured by
UV-HPLC of 11% (Table 1).
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Table 1. Clinical and biochemical data from positive NBS patients, symptomatic adults and obligate heterozygotes.
Cell
Line
Age at Time of
Investigation/Diagnosis
Detail/Presumed
Diagnosis
NBS Cut off and Day
of Screen C14:1
µmol/L < 0.6 Day 1
Mutation 37
◦C
Oleate %
41 ◦C
Oleate %
HPLC
% Current Age Follow Up
77 Neonate False positive screen1 mutation only 1.11
Heterozygous
c.848T>C (p.Val283Ala) 70 66 84
6 years 7
months
Asymptomatic; 10 month
follow up
78 Neonate False positive screen1 mutation only 1.21
Heterozygous
c.1316G>A (p.Gly439Asp) 66 70 40
6 years 8
months
Asymptomatic; 10 month
follow up
76 Neonate False positive screen1 mutation only 0.79
Heterozygous
c.848T>C (p.Val283Ala) 93 134 87
6 years 9
months Asymptomatic; 9 month follow up
37 Neonate False positive screen1 mutation only 1.21
Heterozygous
c.897G>C (p.Lys299Asn) 74 83 29
6 years 10
months Remains asymptomatic
91 Neonate False positive screen2 mutations 1.08
c.1405C>T (p.Arg469Trp)
c.686G>A (p.Arg229Gln) 66 66 117
5 years 9
months
Asymptomatic; 5 year 2 month
follow up
78 Neonate False positive screenNo mutation 0.91 No mutations detected 90 93 138
6 years 10
months Asymptomatic; 8 month follow up
* NBS cut off
< 1.3 Day 2
17 Neonate False positive screen 2.14 Homozygousc.1226C>T (p.Thr409Met) 120 126 70
4 years 6
months Well. No more ER. Discharged
519 Neonate False positive screen 2.98 Homozygousc.1226C>T (p.Thr409Met) 122 155 NA
5 years 2
months Well. No more ER. Discharged
12 Neonate
True positive screen. Treated
from birth. Previous sib died
of VLCAD on day 1 of life
5.45
c.942_947delAGTACG
(p.Arg316_Val317del)
c.343delG (p.(Glu115fs))
8 8 NA 4 years 1month
Severe infantile: Treated from birth
with MCT and ++ calories. High
CK despite high calorie and MCT
diet and overnight feeding
233 Neonate
True positive screen.
Avoidance of fasting,
emergency regimen
6.9 c.848T>C (p.Val283Ala)c.1616C>A (p.Ala539Asp) 29 16 NA
3 years 10
months
On normal diet, max fasting time
of 12 h + ER. Yearly CK, Liver USS,
echo. Asymptomatic
18 Neonate True positive screen 8.2
c.622G>C (p.Gly208Arg)
last nucleotide in
exon—likely to be splicing
mutation.
c.1838G>A (p.Arg613Gln)
29 17 11 4 years 2months
Loose low fat, high MCT diet.
Short fasting time. Strict ER. At 4
years, resting CK increased, corn
starch introduced
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Table 1. Cont.
Cell
Line
Age at Time of
Investigation/Diagnosis
Detail/Presumed
Diagnosis
NBS Cut off and Day
of Screen C14:1
µmol/L < 0.6 Day 1
Mutation 37
◦C
Oleate %
41 ◦C
Oleate %
HPLC
% Current Age Follow Up
16 Neonate Uncategorisedpositive screen 3.81
c.1226C>T (p.Thr409Met)
c.1616C>A (p.Ala539Asp) 63 64 NA
4 years 5
months
Well. No medical problems.
No diet. Self-discharged
22 Neonate
Uncategorised positive
screen. Avoidance of fasting,
emergency regimen
2.73 c.1226C>T (p.Thr409Met)c.1322G>A (p.Gly441Asp) 56 21 24
4 years 9
months Well. Discharged
52 # Symptomatic adult
Uncategorised. Single
episode of hyperthermia and
rhabdomyolysis following
unaccustomed extended
aerobic exercise, became
encephalopathic,
hospitalised and developed
multi-organ failure. No
biochemical markers
suggestive of VLCAD. CPT2
deficiency excluded
Within normal
reference range
Heterozygous
c.1837C>T (p.Arg613Trp) 56 46 38
19 # Symptomatic adult
Uncategorised. Atypical
neurological symptoms not
suggestive of VLCAD. No
history of hypoglycaemia or
rhabdomyolysis. CPT2,
LCHAD, TFP also excluded
Within normal
reference range
Heterozygous
c.1019G>T (p.Gly340Val)
+ c.753-27C>T Possible
double mutant allele,
identical genotype detected
in an unrelated newborn
(unpublished data)
55 46 21
32 Adult obligate heterozygote NA Heterozygousc.1360G>A (p.Asp454Asn) 107 NA NA Asymptomatic
33 Adult obligate heterozygote NA Heterozygousc.1375C>T (p.Arg459Trp) 103 NA NA Asymptomatic
34 Adult obligate heterozygote NA Heterozygousc.848T>C (p.Val283Ala) 51 52 32 Asymptomatic
35 Adult obligate heterozygote NA None detected 71 63 87 Asymptomatic
Red, known pathogenic mutation; NA, data not available/not analyzed; # [20]; ER, emergency regimen; CK, creatine kinase; MCT, medium chain triglyceride; CPT2, carnitine
palmitoyltransferase type 2; LCHAD, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency; TFP, trifunctional protein deficiency; NB, Two obligate carriers gave oleate flux >100% of
controls at 37 ◦C and therefore were not assayed at 41 ◦C and not included in this table; * Current cut-off is C14:1 ≥2.5.
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Informed Consent: Informed consent was obtained from all patients, their parents or legal
guardians prior to obtaining skin biopsies for fibroblast studies in countries where this was required
by law.
Two infantile patients remain uncategorized as both have a copy of the common “benign” Pacific
c.1226C>T mutation plus one other mutation [5]. In one uncategorized case, the second mutation is a
known pathogenic mutation (cell line 22) and in the other case the second mutation is of unknown
pathogenicity (cell line 16) (Table 1). Two adults with clinical disease possibly attributable to reduced
VLCAD activity also remained uncategorized as both were shown to have at least one mutation in
the VLCAD gene (Table 1). We also included four adult obligate heterozygotes, i.e., parents of a
VLCAD patient.
3. Methods
Flux assays were performed in multi-well plates and each assay measured FAO-flux in 9 patient
cell lines (2 substrates in duplicate, 4 wells for each patient) as previously described [18,22,23]. Results
were calculated in pmol H2O h−1 (mg fibroblast protein) −1 and the cumulative data for the assay used
to calculate the percentage activity towards each substrate for each cell line. Cell lines with activities
<70% towards either of the two substrates were then removed from the calculation and the remaining
cell lines designated as simultaneous normal controls. The simultaneous normal control results were
used to generate a mean normal control activity for each substrate. Cell line(s) from patients with
reduced FAO-flux were expressed as percentage activity of the assay normal control mean for each
substrate. Each assay generally consisted of 5–8 simultaneous normal control cell lines. Every cell line
was assayed at least twice and VLCADD cell lines and screen positive cell lines were assayed up to
12 times. Fibroblasts were routinely grown and assayed at 37 ◦C, but some cell lines were also grown
and assayed at 41 ◦C. Fibroblasts were grown at 41 ◦C for seven days prior to FAO-flux assay in order
to unmask cell lines expressing thermolabile mutant protein [24,25]. Wherever possible we grew and
assayed cell lines at 41 ◦C where residual oleate flux was >20% at 37 ◦C.
A different mix of normal control cell lines were used for each assay to more broadly reflect
general normal control activity under the existing cell culture and laboratory conditions at that time.
Internal quality control was achieved by periodically testing stored samples from known patients
with a diagnosed fatty acid oxidation disorder. Fibroblast cell lines were low passage, generally
passage 3–10, and results were comparable over the study period as results for each assay were
expressed as a percentage of simultaneous normal control cell lines grown and assayed under the same
conditions. Graphical representation of FAO-flux results is plotted for each patient as the calculated
mean percentage activity for all assays for each substrate measured at the stated temperature. Control
data is graphically represented by plotted results from a series of control cell lines selected at random.
Specific VLCAD activity was measured by the method of Wanders et al. 2010 [15]. Detection of
the products C16-CoA(OH) and C16:1-CoA was by UV-HPLC at 260 nm following incubation of
fibroblast sonicates in 125 mmol/L Tris-HCL buffer, 0.4 mmol/L ferrocenium hexafluorophosphate,
and 0.25 mmol/L palmitoyl-CoA at pH 8.0. Fibroblast protein was by Pierce™ BCA Protein Assay
(Thermo-Scientific, Waltham, MA, USA).
Ethical Standards: All procedures followed were in accordance with ethical standards of the
Helsinki Declaration of 1975, as revised in 2000.
4. Results
The UV-HPLC enzyme method clearly discriminated VLCADD cell lines from control cell lines
in our series of 14 VLCADD patients (Figure 1). Plotting percent oleate flux against VLCAD enzyme
activity showed a reasonably good correlation between the two methods with narrow separation
between VLCADD patients and all other groups at a cut off value of≤41% oleate flux at 37 ◦C (Figure 2).
Seven patients who presented clinically as infants gave enzyme activities of 0.6 ± 1.0 nmol/mg/min,
normal control activity 14.1 ± 5.3 (n = 17). However, there was disparity between oleate FAO-flux
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at 37 ◦C and the UV-HPLC method at enzyme activities between 20% and 35%. This manifests as
an overlap between cell lines from three myopathic VLCADD patients, two uncategorized patients,
one obligate heterozygote and one false positive screen (Figure 1).
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were also grown and assayed at 41 °C. The results of the VLCADD cell lines with low FAO-flux at 37 
°C are also plotted to demonstrate the merging of the two groups following temperature stress of 19 
high residual FAO-flux cell lines. This results in all VLCADD cell lines having an oleate FAO-flux of 
≤30% with 60/69 cell lines giving activity of <20% (Figure 3). 
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Figure 2. Percentage FAO-flux in infantile and myopathic VLCADD vs. controls at 37 ◦C.
Results of flux assays at 37 ◦C show clear separation of all VLCADD cell lines from controls by
plotting percentage oleate FAO-flux against percentage myristate FAO-flux (Figure 2). A degree of
separation between infantile and myopathic phenotypes is clearly discernible, although there is some
overlap between the two groups.
Plotting fibroblast FAO-flux results obtained at 41 ◦C after growing and assaying 19 VLCADD
cell lines that exhibited high residual FAO-flux >20% at 37 ◦C is shown in Figure 3. Control cell lines
were also grown and assayed at 41 ◦C. The results of the VLCADD cell lines with low FAO-flux at
37 ◦C are also plotted to demonstrate the merging of the two groups following temperature stress of
19 high residual FAO-flux cell lines. This results in all VLCADD cell lines having an oleate FAO-flux of
≤30% with 60/69 cell lines giving activity of <20% (Figure 3).
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and 22), both compound heterozygous for the “mild” c.1226C>T mutation plus a second mutation, 
gave oleate FAO-flux of 63% and 56%, respectively, which plot between the VLCADD and normal 
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screened infants and four uncategorized cell lines at 37 °C as compared to normal controls. 
The FAO-flux results for the cell lines listed in Table 1 following growth and assay at 41 °C are 
plotted along with the symptomatic VLCADD group (Figure 5). The highest percent oleate FAO-flux 
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plotted along with results obtained at 37 ◦C in VLCADD cell lines with low FAO-flux.
FAO-flux results obtained at 37 ◦C in cell lines from 13 positive NBS screened patients (eight
false positive, three true positive, and two uncategorized cell lines), two uncategorized adult cell
lines and cell lines from four obligate carriers are shown plotted with symptomatic VLCADD cell
lines (Figure 4). Details of these patients are set out in Table 1. All eight of the false positive NB
screened infant cell lines are clearly separated from the symptomatic VLCADD cell lines and segregate
with/towards th normal control group (Figure 4). The three true positive screened cell lines segregate
with the clinically symptomatic VLCADD group. Three of the adult obligate heterozygo es (cell lines
32, 33, and 35) give FAO-flux of 107%, 103% and 71%, respectively, and segregate with the normal
control group. Two uncategorized positive screene infants (cell lines 16 and 22), both comp und
heterozygous for the “mild” c.1226C>T mutation plus a second mutation, gave oleate FAO-flux of 63%
and 56%, respectively, which plot bet een the VLCADD and normal control groups. Two cell lines
from two adults (cell lines 52 and 19) with clinical symptoms possibly attributable to reduced VLCAD
activity and one of the obligate heterozygotes (cell line 34) gave FAO-flux activity of 56%, 55% and
51%, respectively, which again plots between the clinically affected and the normal control group.
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The FAO-flux results for the cell lines listed in Table 1 following growth and ass y at 41 ◦C are
plotted along with the symptomatic VLCADD group (Figure 5). The highest percent oleate FAO-flux
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in a cell line from a symptomatic VLCADD patient derived at 41 ◦C is 30% and most (60/69) VLCADD
patient cell lines have FAO-flux activity <20%. The uncategorized positive screen (cell line 22) that
gave 56% oleate flux at 37 ◦C shows reduction of activity at 41 ◦C to 21% and now segregates with
the symptomatic VLCADD group. The two uncategorized adults (cell lines 52 and 19) only show
relatively small reductions in FAO-flux at 41 ◦C both giving oleate flux of 46% and remain segregated
roughly equidistant between the normal control group and symptomatic VLCADD group. The obligate
heterozygote (cell line 34) gives an oleate FAO-flux of 52%, which again plots between the normal
control group and the symptomatic VLCADD cell lines. However, all three cell lines do not segregate
with the symptomatic VLCADD group and would therefore be considered as “low risk” patients with
regards to developing clinical symptoms related to VLCAD deficiency.
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5. Discussion
We have measured fatty acid oxidation flux in over 7000 patient cell lines over the past 25 years
using the substrates [9,10-H3]myristic acid, [9,10-H3]palmitic acid and [9,10-H3]oleic acid. In this
study, we have only reported myristate and oleate FAO-flux as these two substrates alone provide the
necessary relevant information for the diagnosis of VLCADD. Currently, we perform FAO-flux assays
on approximately 340 cell lines annually.
We have a confirmed diagnosis of VLCADD in 69 symptomatic patients and most have molecular
confirmation with the finding of two mutations in the ACADVL gene. However, specific details of
mutations are not available for all patients. In this study, we have compared results of the VLCAD
enzyme assay to oleate FAO-flux assay at 37 ◦C in a limited number of patients. Although there
was relatively good correlation between the two assays, there was a clear indication that the enzyme
assay in fibroblasts could not separate some heterozygotes from cell lines obtained from clinically
symptomatic VLCADD patients at enzyme activities of approximately 20% to 35% of the control mean.
Inconclusive classification of patients using molecular and biochemical assays including the use of
a similar enzyme assay in lymphocytes have previously been reported [11,26]. An example of such
disparity in the present study was that one symptomatic VLCADD cell line (Figure 1) gave enzyme
activity of 31%, while a false positive screen infant (cell line 91) and an obligate heterozygote (cell line
34) gave enzyme activity of 32% and 29%, respectively (Figure 1,Table 1). The VLCADD patient in
question had a high residual oleate FAO-flux of 41% at 37 ◦C (Figure 2), but this fell to 15% at 41 ◦C,
which clearly identified her as an “at risk” VLCADD patient. This same patient was diagnosed with
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VLCADD in her 60s and shown to have two known pathogenic mutations in ACADVL gene. She had
suffered with repeated episodes of rhabdomyolysis since childhood but was well between episodes
with normal creatine kinase and normal muscle strength.
In this study, we have graphically plotted the percent FAO-flux of cell lines from symptomatic
VLCADD patients and shown that these are clearly separated from normal control cell lines both at 37
and 41 ◦C (Figures 1 and 2). This provides us with data with which to compare NBS positive infants and
allows us to ascribe a degree of clinical risk for each presumptive positive patient. However, we do not
know if all patient that segregate with the clinically affected groups will develop symptomatic disease,
as many factors may influence clinical expression of the defect [7,27] and it is suggested that some
patients with high residual enzyme activity even with two mutations may remain asymptomatic [11,16].
However, using myristate and oleate FAO-flux, we have clearly segregated eight false positive screen
patients with the control group and three true positives with the symptomatic VLCADD group.
We have also shown that by incubating and assaying fibroblasts at 37 ◦C and in the case of two
obligate heterozygote cell lines, also at 41 ◦C, we have segregated four asymptomatic adult obligate
heterozygotes away from the symptomatic VLCADD cell lines. In addition, in the present study, results
of cell lines from two symptomatic adults, although not segregating with the clinically presenting
VLCADD cases, plotted equidistant between the controls and symptomatic VLCADD cell lines.
This indicates that, in some patients, there may remain some unresolved questions as to any likely
contribution of a moderate reduction in VLCAD activity to the development of clinical disease.
Interestingly two screen positive infants carrying the “benign” Pacific mutation c.1226C>T plus a
second mutation gave somewhat equivocal oleate flux results at 37 ◦C of 63% and 56%, respectively
(Table 1), which would suggest a relatively low risk, as these did not segregate within the symptomatic
VLCADD group. On stressing the fibroblasts at 41 ◦C, however, cell line 22 segregated with the
symptomatic VLCADD group while cell line 16 segregated with the normal controls (Figure 5).
This could be explained by their second mutation. Cell line 22 carries the c.1322G>A (p.Gly441Asp)
mutation, which has been reported in several clinically affected infants [8,9,28,29], whereas patient 16
has the c.1616C>A (p.Ala539Asp) mutation, which has not been reported in clinically affected patients
and is at present a variant of unknown clinical significance. Both patients remain well however and
have been discharged (Table 1).
We know of one young adult patient in our series (data not plotted) who remained asymptomatic
despite his younger sister presenting primarily with a myopathic phenotype, although both patients
carried the same mutations and had similarly low flux results (oleate flux at 41 ◦C of 23% and 26%,
respectively). The concern that over-diagnosing patients who may not have clinical problems until
adolescence or adulthood or indeed at all, is a legitimate concern [30]. However, several patients that
have been diagnosed as “myopathic” VLCADD in this study have, on closer investigation of their
clinical record, been reported as presenting as infants or young children with one or several episodes
of hypoglycemia. This supports the idea that even “milder” phenotypes may present in infancy given
sufficient metabolic stress. Equally although most infantile phenotypes in this study had low oleate
flux at 37 ◦C i.e., 42/46 <20%, one infant who presented with an episode of low blood glucose gave
a high residual oleate flux of 41% at 37 ◦C (Figure 2), however this fell to 11% at 41 ◦C. This might
also indicate that given sufficient metabolic stress in infancy/childhood there may be precipitation
of hypoglycemic crisis even in some patients with significant residual enzyme function. We would
suggest that it is important to identify even potentially mild phenotypes to avoid the possibility of
metabolic decompensation and serious clinical sequelae. Similarly, in the case of MCADD, it is widely
accepted that not all patients homozygous for the common c.985A>G mutation will present with
clinical disease during their life time although MCADD is universally accepted as fitting the recognized
newborn screening criteria [31].
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6. Conclusion
The combined use of [9,10-H3]myristic acid and [9,10-H3]oleic acid FAO-flux at both 37 ◦C and
41 ◦C will separate clinically symptomatic VLCADD patients from simple heterozygotes and offers a
reliable way of ascribing a degree of clinical risk in NB screen positive infants where other biochemical
and molecular markers are inconclusive. In addition, plotting results of FAO-flux data obtained at
37 ◦C provides useful information with regards to the likely clinical phenotype of the patient.
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